Company Reaches $1.4 Billion Settlement in Opioid Treatment Investigation
MONDAY, July 15, 2019 -- A drug company has reached a $1.4 billion settlement with the U.S. government over an investigation into the company's marketing and sales of a prescription drug used to treat opioid addiction.
From 2010 through 2014, the Reckitt Benckiser Group or its subsidiaries mishandled the marketing or improperly controlled the pricing of the drug Suboxone (buprenorphine and naloxone), government officials alleged, CNN reported. In a statement, Reckitt Benckiser said it has "has acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct."
"Drug manufacturers marketing products to help opioid addicts are expected to do so honestly and responsibly," Jody Hunt, assistant attorney general in the Civil Division of the U.S. Justice Department, said in a department news release.
This settlement is the largest in U.S. history in a case involving an opioid medication, CNN reported.
© 2020 HealthDay. All rights reserved.
Posted: July 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.